BioMedNewsBreaks – IBN, BioMedWire to Provide Dedicated Media Coverage for Upcoming BioPharma Nexus Events

InvestorBrandNetwork (“IBN”), a dynamic communications organization, today announced its collaboration with BioPharma Nexus as an official media partner for its events this month. In addition, BioMedWire, a specialized communications platform dedicated to the life sciences sector and a key part of IBN’s Dynamic Brand Portfolio (“DBP”), will serve as an official media partner. For each of the events, IBN and BioMedWire will leverage advanced communications tools to provide dedicated coverage, including syndicated article dissemination throughout IBN’s extensive network of 5,000+ strategic partners, and offer updates on each event via IBN’s influential social media accounts. “It is a pleasure to work with IBN and BioMedWire,” said Asad Ali, head of operations for BioPharma Nexus. “They have proved invaluable in developing our targeted outreach, delivering high visibility to our sponsors, partners and speakers across multiple audiences via trusted brands.”

To view the full press release, visit https://ibn.fm/j1lhF

About IBN

IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (“DBP”), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Publishes Peer-Reviewed Validation of Deciparticle(TM) Platform 

Oncotelic Therapeutics (OTCQB: OTLC), together with Sapu Nano, announced the publication of a peer-reviewed manuscript in the International Journal of…

15 hours ago

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Launches AI Agent Platform for Patient Scheduling and Care Coordination

HealthLynked (OTCQB: HLYK) announced the launch of its next-generation AI Agent Platform, a conversational voice AI…

18 hours ago

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Expands AI Voice Analytics Beyond Traditional Screening

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio…

4 days ago

BioMedNewsBreaks — BioAdaptives, Inc. (OTC: BDPT) MyndRenew(TM) Earns TruShield Certification

BioAdaptives (OTC: BDPT) announced that MyndRenew(TM), the nighttime component of its MyndSystem(TM) cognitive health platform, has received TruShield Certified status, confirming compliance with…

4 days ago

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in NetworkNewsAudio Editorial on DNA Repair Therapies 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.  Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced…

4 days ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in NetworkNewsAudio Editorial on Multiple Sclerosis

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid…

4 days ago